@article{98096,
  keywords = {LPRF, Leukocyte and Platelet-Rich Fibrin Therapy, Leprosy, Nepal, Resistance},
  author = {Houghton F and Stritch M and Tamang K and Winterburn M},
  title = {Leukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy:: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings},
  abstract = {<p>This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.</p>
},
  year = {2022},
  journal = {Medicina Internacia Revuo },
  volume = {30},
  publisher = {Universala Medicina Esperanto Asocio},
  url = {https://interrev.com/mir/index.php/mir/article/view/207/158},
  language = {Eng},
}